These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26293390)

  • 41. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening.
    Baker MW; Groose M; Hoffman G; Rock M; Levy H; Farrell PM
    J Cyst Fibros; 2011 Jul; 10(4):278-81. PubMed ID: 21388895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
    Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
    BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunoreactive trypsinogen in healthy newborns and infants with cystic fibrosis.
    Fingerhut R; Rueegg CS; Imahorn O; Pedersen ESL; Kuehni CE; Gallati S; Regamey N; Barben J
    Arch Dis Child Fetal Neonatal Ed; 2023 Mar; 108(2):176-181. PubMed ID: 36351789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Refinement of newborn screening for cystic fibrosis with next generation sequencing.
    Rock MJ; Baker M; Antos N; Farrell PM
    Pediatr Pulmonol; 2023 Mar; 58(3):778-787. PubMed ID: 36416003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland.
    Barben J; Gallati S; Fingerhut R; Schoeni MH; Baumgartner MR; Torresani T;
    J Cyst Fibros; 2012 Jul; 11(4):332-6. PubMed ID: 22300503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    Padoan R; Bassotti A; Seia M; Corbetta C
    Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
    Ellery KM; Kopp B; Conwell DL; Gariepy C
    Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neonatal screening for cystic fibrosis].
    Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
    An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis.
    Padoan R; Genoni S; Moretti E; Seia M; Giunta A; Corbetta C
    Acta Paediatr; 2002; 91(1):82-7. PubMed ID: 11883825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic Signatures of Cystic Fibrosis Identified in Dried Blood Spots For Newborn Screening Without Carrier Identification.
    DiBattista A; McIntosh N; Lamoureux M; Al-Dirbashi OY; Chakraborty P; Britz-McKibbin P
    J Proteome Res; 2019 Mar; 18(3):841-854. PubMed ID: 30507207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cystic fibrosis newborn screening in Switzerland - evaluation and scenarios for improvement after 11 years of follow-up.
    Pedersen E; de Jong Carmen CM; Jurca M; Berger DO; Sanz J; Sluka S; Poms M; Baumgartner MR; Regamey N; Kuehni CE; Barben J; Rueegg CS;
    J Cyst Fibros; 2024 Jul; 23(4):796-803. PubMed ID: 38658252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
    Seror V; Cao C; Roussey M; Giorgi R
    J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
    Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
    Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.
    Rock MJ; Mischler EH; Farrell PM; Bruns WT; Hassemer DJ; Laessig RH
    Pediatr Pulmonol; 1989; 6(1):42-8. PubMed ID: 2704582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study.
    Baker MW; Atkins AE; Cordovado SK; Hendrix M; Earley MC; Farrell PM
    Genet Med; 2016 Mar; 18(3):231-8. PubMed ID: 25674778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
    Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
    Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome data from 15 years of cystic fibrosis newborn screening in a large UK region.
    Driscoll SJ; Heinz K; Goddard P; Desai M; Gilchrist FJ
    Arch Dis Child; 2024 Mar; 109(4):292-296. PubMed ID: 37973197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
    Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
    Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neonatal cystic fibrosis screening: Analysis and differences in immunoreactive trypsin levels in newborns with a positive screen.
    Arrudi-Moreno M; García-Romero R; Samper-Villagrasa P; Sánchez-Malo MJ; Martin-de-Vicente C
    An Pediatr (Engl Ed); 2021 Jul; 95(1):11-17. PubMed ID: 34140271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.